HSD17B13 and metabolic dysfunction-associated steatotic liver disease: Hepatic expression of HSD17B13 has been shown to be significantly higher in MASLD patients, while the protective variant (rs72613567 T>TA) is associated with a decrease in fibrogenic pathways [10,13,14].